ECONOMY — June 24, 2026
Domestic medicine production share in Afghanistan rises above 40 percent, health ministry says
Deputy Minister Mawlavi Hamdullah Zahid highlighted the progress at a meeting with representatives of 22 factories and called for Good Manufacturing Practice certification along with reduced import dependence.
The Ehtebar Desk — originates with Pajhwok — 2 min read
The Ministry of Public Health reported that the share of medicines and health products produced domestically in Afghanistan has risen to more than 40 percent.
This marks an increase from less than 5 percent in previous years. Deputy Minister for Food and Medicine Mawlavi Hamdullah Zahid made the remarks during a consultative meeting with representatives of 22 pharmaceutical and health product manufacturing factories.
He stressed support for local production, the need to obtain Good Manufacturing Practice certification, quality improvement and efforts to reduce reliance on imports to achieve self-sufficiency. Industry officials and technical advisers also attended the meeting.
Read the original reporting at Pajhwok →
Reliability assessment
Single source provides direct, on-record attribution from named public official Mawlavi Hamdullah Zahid (deputy minister) with concrete details including meeting participants, GMP focus, and specific production percentages.
The source language reads straight.
Independent web corroboration
An independent web search turned up no separate corroborating reports. Treat the account as single-sourced until more outlets pick it up.
Across the newsrooms
Filed by
Pajhwok
Originating
Reported straight
Reported straight
Filed under
Economy — MoPH, pharmaceutical production, domestic medicine, self-sufficiency, GMP
Spotted an error or have more on this story? Tip the desk on Telegram → or WhatsApp →.
Reader supported
Keep Ehtebar running
Every published story uses paid tools to translate reporting, compare sources, extract claims, and produce a clearer read on Afghanistan. Reader support helps keep that work independent.
€5
helps cover daily verification runs
€15
supports a week of source comparison
€50
keeps independent analysis moving
